Lymphocytotoxins are antibodies which bind on to the surfaces of lymphocytes and in the presence of complement cause cell lysis. Lymphocytotoxins (LCA) may be either IgM or IgG immunoglobulins; the former are cold reacting (optimum 15-170C) while the latter are warm reacting (optimum 370).1 LCAs are found in the serum of normal individuals following a variety of bacterial or viral infections and after vaccination and immunisation.2 They are found also in many inflammatory and autoimmune diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).3 LCAs in juvenile chronic arthritis and SLE have been considered as possible candidates in the development of some of the disturbed immune function seen in these diseases, since they may inactivate or kill suppressor T cells and T cells responding to mitogens. 4 5 In rheumatoid arthritis (RA) some 35-50%/0 of patients may Table 2 shows the relationship between the number of lymphocytes of the panel killed by a particular serum (frequency) and the strength of killing. It can be seen that those sera which showed strong cytotoxicity also reacted with more members of the lymphocyte panel (X2 = 20x4; P<0.001). Having shown this relationship we then analysed strength of reactivity against the HLA DR antigen status of the serum donor. The relationship found was that between HLA DR3 and the presence of strongly reactive LCAs (Table 3 (a), x2 = 5x77, P<0 025), and HLA DR4 with the presence of weakly reactive LCAs (Table 3 (b), x2 = 5x00, P<0 025). The association of LCAs with HLA DR4 described in this study is remarkable, considering the high overall frequency of DR4 in the RA patients (59 %). In view of the association of HLA DR4 with both RA itself and the occurrence of LCAs in the disease, it is particularly relevant to investigate LCAs in RA families. The role of these antibodies and their relationship to immune responsiveness and immunogenetic status may prove of particular importance in the rheumatic diseases. 
